Merck Beats Estimates With Blockbuster Drugs

Merck reported robust third-quarter financial results, with revenue climbing to $18.1 billion, surpassing market expectations. The company's blockbuster cancer drug, Keytruda, and its HPV vaccine, Gardasil, were significant drivers of this success.

Sales for Keytruda, a leading immunotherapy, increased by 6% to $8.6 billion, including contributions from its newer subcutaneous version. Gardasil also showed a substantial 14% rise in sales, recovering from recent weaker performance in China. These strong performances allowed Merck to raise its full-year revenue and earnings per share forecasts.

The company is actively diversifying its portfolio beyond Keytruda, which faces patent expirations in 2028. Recent developments include positive trial data for an mRNA cancer vaccine developed with Moderna. Additionally, the pulmonary arterial hypertension drug Winrevair showed significant sales growth.

Merck's stock has seen considerable gains this year, outperforming the broader market, reflecting investor confidence in its current product lineup and future strategies.